Pricing Log in Create free account

Smith & Nephew SNATS, Inc. (SNN) vs 10x Genomics (TXG)

Smith & Nephew SNATS, Inc. and 10x Genomics are both Medical Devices companies. Smith & Nephew SNATS, Inc. is the larger, with a market value of $13.4B against $7.6B — 1.8× the size. 10x Genomics has negative trailing earnings, so its P/E is not meaningful; Smith & Nephew SNATS, Inc. trades at 38.9×. Smith & Nephew SNATS, Inc. grew revenue faster over the last twelve months: 4.81% against −4.28%. Smith & Nephew SNATS, Inc. has the higher net margin (6.71% vs −12.2%) and the higher return on invested capital (0.00% vs −20.2%). Across the 20 metrics below, Smith & Nephew SNATS, Inc. leads on 15 and 10x Genomics on 5.

Valuation

Metric SNN TXG Medical Devices median
P/E 38.94 n/m 25.58
P/S 1.37 12.35 2.54
P/B 2.77 9.23 2.48
Price to free cash flow 7.09 63.28 28.81
EV/EBITDA 6.54 n/m 11.51
EV/Sales 1.60 11.51 2.72
Earnings yield 2.57% (1.01%) (12.82%)
Free cash flow yield 14.10% 1.58% (8.18%)

Profitability

Metric SNN TXG Medical Devices median
Gross margin 70.52% 70.03% 57.76%
Operating margin 0.00% (14.33%) (15.07%)
Net margin 6.71% (12.18%) (14.45%)
Free cash flow margin 0.00% 19.68% (3.88%)
Return on equity 0.00% (9.40%) (10.35%)
Return on assets 0.00% (7.47%) (17.26%)
Return on invested capital 0.00% (20.20%) (5.27%)

Growth

Metric SNN TXG Medical Devices median
Revenue growth (TTM) 4.81% (4.28%) 10.41%
EPS growth (last fiscal year) 52.34% 76.97% 28.17%
Revenue growth, 5-year CAGR 6.21% 16.55% 15.74%
Net income growth, 5-year CAGR 6.89% 0.00% 0.00%

Health

Metric SNN TXG Medical Devices median
Debt to equity 0.62 0.00 0.04
Current ratio 2.14 5.69 2.74
Net debt to EBITDA 1.92 30.49 0.54

Dividend

Metric SNN TXG Medical Devices median
Dividend yield 2.49% — 1.02%
Payout ratio — — 0.37

Size

Metric SNN TXG Medical Devices median
Market cap 13.40b 7.56b 239.53m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack